Overview

The AVENIO ctDNA Surveillance Kit is a next-generation sequencing (NGS) liquid biopsy assay that’s specially designed and optimized for longitudinal tumor burden monitoring in lung cancer and colorectal cancer (CRC).  The Surveillance panel contains 197 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.

Features and Benefits of AVENIO ctDNA Surveillance Kit

  • Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents, bioinformatics and software
  • Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

Product Highlights

Detection of mutants with exceptional sensitivity and specificity2,3

  • >99% specificity for all classes of mutations
  • >99% positive predictive value (PPV) for SNVs, indels, and fusions and >96% PPV for CNVs

View the detailed Gene List for the AVENIO Surveillance Panel

The Unique Challenges and Opportunities of Circulating Tumor DNA

Presenter: Dan Klass, Ph.D.
Roche

A portfolio of NGS liquid biopsy assays  

The AVENIO ctDNA Surveillance Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 77-gene AVENIO ctDNA Expanded Kit for profiling emerging and guideline-driven biomarkers.